Clinical Trial Update: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076) [Phase 3]

View source ↗

Summary

Phase 3 trial of odanacatib in postmenopausal women previously treated with oral bisphosphonates for osteoporosis has been terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis | Phase 3 | Status: TERMINATED | Results posted: 2017-05-22